Juvenile Myelomonocytic Leukemia clinical trials at UC Cancer
1 research study open to eligible people
open to eligible people ages 1 month to 21 years
This phase II trial studies how well trametinib works in treating patients with juvenile myelomonocytic leukemia that has come back (relapsed) or does not respond to treatment (refractory). Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Our lead scientists for Juvenile Myelomonocytic Leukemia medical studies include Elliot Stieglitz.